Please assess the completion status of the following clinical trial:

Trial Title: Alveolar Management Following Teeth Extraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Indication for tooth extraction resulting in a edentulous gap~* Male and female patients with an age range 20-60 years~* Caucasian~* For female patients: a negative pregnancy test~* Normotonic blood pressure (according to the WHO definition):~  * Men: 110/70 - 140/90 mm Hg~ * Women: 100/60- 140/90mm Hg~Exclusion Criteria:~* Parallel implantation of another implant~* Parallel planned prosthetic restoration of the adjacent teeth~* Smoker (less than 5 years non-smoker)~* Nursing women~* Participation in another clinical trial which dates back to less than 3 months before inclusion in this clinical trial~* Intake of bisphosphonates~* Radiation therapy (medical history or current)~* Known Diabetes mellitus~* Inflammatory processes in the mouth (PSI\> 2)~* Presence of autoimmune diseases (Rheumatoid arthritis, Sjögren's syndrome, Systemic lupus erythematosus)~* Presence of blood coagulation disorders (Haemophilia A/B), or the intake of anticoagulants (Warfarin, new oral anticoagulants, aspirin\> 100 mg)~* Osteogenesis imperfecta~* Osteoporosis~* Leukemia~* Agranulocytosis~* Immunocompromised patients~* Acute phase and rehabilitation phase of myocardial infarction~* Oncogenes diseases~* Patients undergoing chemotherapy~* Sepsis~* Acute and chronic infections: sinusitis, rhinitis, pharyngitis and Otitis media~* Wound healing disorders~* Seizures~* Gingival hyperplasia~* Alcohol abuse~* Drug abuse~* Infectious diseases (HIV, Hepatitis B and C)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Human-Spongiosa (IMP: drug) (Type: ACTIVE_COMPARATOR): Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
- collacone® (IMP: medical device) (Type: ACTIVE_COMPARATOR): Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation

Based on this trial design, predict the completion outcome and termination type (if applicable).